|
Gene: CEP112 |
Gene summary for CEP112 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CEP112 | Gene ID | 201134 |
Gene name | centrosomal protein 112 | |
Gene Alias | CCDC46 | |
Cytomap | 17q24.1 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q8N8E3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
201134 | CEP112 | HCC1_Meng | Human | Liver | HCC | 8.11e-05 | -5.17e-02 | 0.0246 |
201134 | CEP112 | HCC2 | Human | Liver | HCC | 1.51e-03 | 3.14e+00 | 0.5341 |
201134 | CEP112 | S014 | Human | Liver | HCC | 1.43e-10 | 7.49e-01 | 0.2254 |
201134 | CEP112 | S015 | Human | Liver | HCC | 3.79e-04 | 3.59e-01 | 0.2375 |
201134 | CEP112 | S016 | Human | Liver | HCC | 7.81e-24 | 1.13e+00 | 0.2243 |
201134 | CEP112 | RNA-P23T2-P23T2-4 | Human | Lung | MIAC | 4.26e-02 | 8.01e-01 | -0.0272 |
201134 | CEP112 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.03e-18 | 8.47e-01 | -0.2116 |
201134 | CEP112 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 2.67e-04 | 6.43e-01 | -0.1941 |
201134 | CEP112 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 2.72e-12 | 8.21e-01 | -0.2107 |
201134 | CEP112 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.07e-09 | 6.18e-01 | -0.2119 |
201134 | CEP112 | RNA-P3T-P3T-1 | Human | Lung | IAC | 1.59e-05 | 5.90e-01 | 0.1829 |
201134 | CEP112 | RNA-P3T-P3T-2 | Human | Lung | IAC | 1.51e-02 | 4.38e-01 | 0.1835 |
201134 | CEP112 | RNA-P3T-P3T-4 | Human | Lung | IAC | 2.21e-03 | 4.00e-01 | 0.1859 |
201134 | CEP112 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 6.39e-30 | 8.39e-01 | -0.0166 |
201134 | CEP112 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.18e-31 | 8.68e-01 | -0.0132 |
201134 | CEP112 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.04e-33 | 8.25e-01 | -0.013 |
201134 | CEP112 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.52e-31 | 8.67e-01 | -0.0121 |
201134 | CEP112 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 1.92e-04 | 4.93e-01 | -0.0961 |
201134 | CEP112 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.42e-08 | 6.59e-01 | -0.0876 |
201134 | CEP112 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 9.26e-07 | 6.25e-01 | -0.0822 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00315031 | Liver | HCC | protein-containing complex localization | 129/7958 | 220/18723 | 9.38e-07 | 1.42e-05 | 129 |
GO:00315032 | Lung | IAC | protein-containing complex localization | 42/2061 | 220/18723 | 2.60e-04 | 4.32e-03 | 42 |
GO:003150311 | Lung | AIS | protein-containing complex localization | 39/1849 | 220/18723 | 2.24e-04 | 4.51e-03 | 39 |
GO:00315037 | Thyroid | PTC | protein-containing complex localization | 107/5968 | 220/18723 | 1.47e-07 | 2.82e-06 | 107 |
GO:003150316 | Thyroid | ATC | protein-containing complex localization | 108/6293 | 220/18723 | 1.33e-06 | 1.69e-05 | 108 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CEP112 | SNV | Missense_Mutation | novel | c.2851N>C | p.Tyr951His | p.Y951H | Q8N8E3 | protein_coding | tolerated_low_confidence(0.45) | benign(0.04) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CEP112 | SNV | Missense_Mutation | novel | c.521C>A | p.Pro174Gln | p.P174Q | Q8N8E3 | protein_coding | tolerated(0.06) | possibly_damaging(0.474) | TCGA-WX-AA46-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CEP112 | SNV | Missense_Mutation | c.693N>T | p.Met231Ile | p.M231I | Q8N8E3 | protein_coding | tolerated(0.34) | benign(0.022) | TCGA-44-6144-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
CEP112 | SNV | Missense_Mutation | c.1541N>C | p.Cys514Ser | p.C514S | Q8N8E3 | protein_coding | tolerated(1) | benign(0.005) | TCGA-49-AARE-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
CEP112 | SNV | Missense_Mutation | rs781683706 | c.1160N>G | p.Asp387Gly | p.D387G | Q8N8E3 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-55-8301-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PR |
CEP112 | SNV | Missense_Mutation | c.2711N>T | p.Arg904Leu | p.R904L | Q8N8E3 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-86-8358-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
CEP112 | SNV | Missense_Mutation | rs774572812 | c.1376N>A | p.Arg459His | p.R459H | Q8N8E3 | protein_coding | tolerated(0.55) | benign(0.003) | TCGA-86-8358-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CEP112 | SNV | Missense_Mutation | c.2766N>T | p.Glu922Asp | p.E922D | Q8N8E3 | protein_coding | deleterious(0) | probably_damaging(0.915) | TCGA-86-A456-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CEP112 | SNV | Missense_Mutation | c.2348A>T | p.Glu783Val | p.E783V | Q8N8E3 | protein_coding | deleterious(0) | possibly_damaging(0.827) | TCGA-95-7039-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
CEP112 | SNV | Missense_Mutation | c.2585G>T | p.Arg862Ile | p.R862I | Q8N8E3 | protein_coding | deleterious(0.01) | benign(0.387) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |